[EFFECT] Exagen Inc. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

EFFECT

Rhea-AI Filing Summary

07/03/2025 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	July 2, 2025 4:01 P.M.

Form:

S-3

CIK:	0001274737
Company Name:	EXAGEN INC.
File Number:	333-288199

Source: View Original Filing on SEC EDGAR

Exagen Inc.

NASDAQ:XGN

XGN Rankings

#7269 Ranked by Market Cap

N/A Ranked by Dividends

#113 Top Gainer

XGN Latest News

Jul 15, 2025

Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

Jun 23, 2025

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

May 9, 2025

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

May 8, 2025

Exagen Inc. Prices Public Offering of Common Stock

May 7, 2025

Exagen Inc. Announces Proposed Public Offering of Common Stock

XGN Latest SEC Filings

Jun 20, 2025

[S-3] Exagen Inc. Shelf Registration Statement

XGN Stock Data

Market Cap 152.15M

Float 13.98M

Insiders Ownership 27.64%

Institutions Ownership 54.26%

Short Percent 0.13%

Industry Diagnostics & Research

Sector Services-medical Laboratories

Website Link

Country United States

City VISTA